Enalare Files Additional Patent Application for Lead Compound ENA-001 - Enhancing Potential Global Exclusivity Through 2042
Jan 7, 2022
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has filed a Provisional Patent Application with the United States Patent and Trademark Office directed to parenteral formulations of ENA-001 and related compounds. The patent application encompasses the Company's developmental formulation candidates for its future proposed clinical trials. Any resultant patent claiming priority to this filing will have an estimated term to 2042.
Enalare is developing multiple agnostic respiratory stimulant products with the potential to improve standard of care for millions of patients. In 2021, Enalare formed a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to accelerate development of an intramuscular formulation (IM) for its lead compound, ENA-001, to treat life-threatening respiratory depression in both mass casualty and everyday community drug overdose situations.
"We are pleased to have successfully advanced our formulation development activities and to have filed another new patent application for ENA-001," stated Daniel Motto, Enalare's Chief Operating Officer. "We thank the team at BARDA for their partnership on the intramuscular formulation and look forward to further advancing the development of this potential life-saving product."
This project has been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. 75A50121C00044.
About ENA-001
Enalare's lead compound, ENA-001, is a one-of-a-kind new chemical entity (NCE) designed as an agnostic respiratory stimulant. The compound has a unique mechanism of action that affects ventilation via the peripheral chemoreceptor pathway in the carotid bodies. The compound utilizes the body's own ventilation control system to beneficially influence breathing and has been shown to be effective and well-tolerated in four previously completed human studies. The Company is currently conducting a breakthrough study evaluating the ability of ENA-001 to reverse the respiratory depressive effects of propofol, a commonly utilized anesthetic in surgical procedures.
About Enalare Therapeutics Inc.
Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening acute respiratory and critical care conditions, including post-operative respiratory depression, community drug overdose, and apnea of prematurity. The Company is planning to initiate additional clinical studies for ENA-001 across multiple indications in the coming year, including for Apnea of Prematurity for which it has received the designation of Rare Pediatric Disease by the FDA.
###
Contact:
Morgan Wagner
Enalare Investor Relations
[email protected]
Press Release Service by Newswire.com
Original Source: Enalare Files Additional Patent Application for Lead Compound ENA-001 - Enhancing Potential Global Exclusivity Through 2042
More News
We bought our £242,000 home without a deposit - here's how
The share of UK mortgages with smaller deposits is the highest it's been since 2008. The BBC spoke to borrowers about how they manage the risks.
The virtual worlds where robots are trained
Training systems that allow robots to negotiate the real world are getting more sophisticated.
Searing Elon Musk Film Nears U.S. Release Amid Overseas Concerns
Alex Gibney’s “Musk” will arrive in United States theaters next month. Universal says it remains committed to releasing it overseas but has yet to set dates.
Trump Seeks ‘Made in U.S.A.’ Labels on Beef as Import Rule Angers Ranchers
The Agriculture Department hopes Americans will pay more for U.S. beef, in an attempt to appease ranchers upset over increased, cheaper imports.
World Bank Courts Private Financing Amid Global Debt Burden
The World Bank president, Ajay Banga, has worked to make the development institution a magnet for private capital as donor nations face budget constraints.
Trump Blasts the Fed But Spares Kevin Warsh After Interest Rate Hike
The president blasted the rest of the Fed — and kept up his demand for a cut — but spared Fed Chairman Kevin M. Warsh from the criticism.
Mixed feelings from consumers as electricity discount to be given to NI households
The one-off £63 reduction in electricity bills will be applied from next month.
Warm words on Canada's EU 'associate membership' but no guarantees
There is no certainty that the idea will ever get off the ground, let alone become a blueprint for other countries, writes the BBC's Katya Adler.
Steve Bannon and Bernie Sanders Condemn Tech ‘Oligarchs’ and Demand A.I. Reforms
At an event in Washington, partisanship took a back seat as elected officials, religious leaders, parents and artists called for reining in artificial intelligence.
Barclays workers ask for more money to return to the office
Unite union, which represents 36,000 Barclays staff, calls for a one-off payment to offset increased travel and childcare costs.
Interest rates held but Bank signals rise if energy prices stay high
Rates are held for the sixth time in a row but the Bank of England says high energy prices make a future rise more likely.
Trump’s Latest Threats Loom Over Fed’s Interest Rate Decision
This month, the president threatened to halt a broad swath of trade if interest rates were not cut, a possibility he resurfaced on Wednesday.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.